{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:55:01Z","timestamp":1793656501449,"version":"4.5.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U24CA076518"],"award-info":[{"award-number":["U24CA076518"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U24CA076518"],"award-info":[{"award-number":["U24CA076518"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U24CA076518"],"award-info":[{"award-number":["U24CA076518"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U24CA076518"],"award-info":[{"award-number":["U24CA076518"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["U24CA076518"],"award-info":[{"award-number":["U24CA076518"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["U24CA076518"],"award-info":[{"award-number":["U24CA076518"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["U24CA076518"],"award-info":[{"award-number":["U24CA076518"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["U24CA076518"],"award-info":[{"award-number":["U24CA076518"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U24CA076518"],"award-info":[{"award-number":["U24CA076518"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U24CA076518"],"award-info":[{"award-number":["U24CA076518"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U24CA076518"],"award-info":[{"award-number":["U24CA076518"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U24CA076518"],"award-info":[{"award-number":["U24CA076518"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000102","name":"U.S. Department of Health & Human Services | Health Resources and Services Administration","doi-asserted-by":"publisher","award":["75R60222C00011"],"award-info":[{"award-number":["75R60222C00011"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000102","name":"U.S. Department of Health & Human Services | Health Resources and Services Administration","doi-asserted-by":"publisher","award":["75R60222C00011"],"award-info":[{"award-number":["75R60222C00011"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000102","name":"U.S. Department of Health & Human Services | Health Resources and Services Administration","doi-asserted-by":"publisher","award":["75R60222C00011"],"award-info":[{"award-number":["75R60222C00011"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000102","name":"U.S. Department of Health & Human Services | Health Resources and Services Administration","doi-asserted-by":"publisher","award":["75R60222C00011"],"award-info":[{"award-number":["75R60222C00011"]}],"id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000006","name":"United States Department of Defense | United States Navy | Office of Naval Research","doi-asserted-by":"publisher","award":["N00014-25-1-2146"],"award-info":[{"award-number":["N00014-25-1-2146"]}],"id":[{"id":"10.13039\/100000006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000006","name":"United States Department of Defense | United States Navy | Office of Naval Research","doi-asserted-by":"publisher","award":["N00014-25-1-2146"],"award-info":[{"award-number":["N00014-25-1-2146"]}],"id":[{"id":"10.13039\/100000006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000006","name":"United States Department of Defense | United States Navy | Office of Naval Research","doi-asserted-by":"publisher","award":["N00014-25-1-2146"],"award-info":[{"award-number":["N00014-25-1-2146"]}],"id":[{"id":"10.13039\/100000006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000006","name":"United States Department of Defense | United States Navy | Office of Naval Research","doi-asserted-by":"publisher","award":["N00014-25-1-2146"],"award-info":[{"award-number":["N00014-25-1-2146"]}],"id":[{"id":"10.13039\/100000006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, was approved in 2022 for heavily pretreated relapsed\/refractory multiple myeloma (RRMM). This study evaluates the safety and efficacy of cilta-cel in RRMM patients reported to the Center for International Blood and Marrow Transplant Research registry between March 2022 and December 2023 who met commercial release specifications. Among 595 patients, median age was 64 years, 57% were male, and 70% had \u22651 comorbidity. Extramedullary disease and marrow plasma cell burden \u2265 50% were present in 13% and 14% of patients, respectively. The median number of prior lines of therapy was 7 and 8% had received prior BCMA-directed therapy. Median follow-up was 12 months (range, 1\u201325 months). Cytokine release syndrome occurred in 80% (\u2265\u2009grade 3: 4%) and immune effector cell\u2013associated neurotoxicity syndrome (ICANS) in 22% (\u2265\u2009grade 3: 4%). Non-ICANS neurotoxicity was seen in 5% (n\u2009=\u200931), including Parkinsonism in 2.7% (n\u2009=\u200916) and cranial nerve palsies in 2.5% (n\u2009=\u200915), primarily cranial nerve VII (n\u2009=\u200912\/15). Infections occurred in 47% and treatment-related mortality was 5%. The best overall response rate was 87%, with \u2265 very good partial response rate in 75%, and \u2265 complete response rate in 35%. Estimated 12-month progression-free and overall survival were 73% (95% CI: 68\u201377%) and 85% (95% CI: 81\u201388%), respectively. This represents the largest standard-of-care (SOC) study of cilta-cel in RRMM patients to date. Despite advanced disease and high comorbidity burden, cilta-cel demonstrated favorable safety and efficacy, supporting its use in clinical practice.<\/jats:p>","DOI":"10.1038\/s41408-026-01496-w","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T17:37:10Z","timestamp":1776188230000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and efficacy of ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma: a CIBMTR study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris K.","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danai","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-1067","authenticated-orcid":false,"given":"Hira","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Devos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruta","family":"Brazauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temitope","family":"Oloyede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-8557","authenticated-orcid":false,"given":"Aimaz","family":"Afrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-4982","authenticated-orcid":false,"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"suffix":"Jr","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-0376","authenticated-orcid":false,"given":"Jesus G.","family":"Berdeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Bidikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-9742","authenticated-orcid":false,"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajoy","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Efebera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Salman","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lohith","family":"Gowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4129-5867","authenticated-orcid":false,"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1875-8966","authenticated-orcid":false,"given":"Abu-Sayeef","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6913-6526","authenticated-orcid":false,"given":"Meera","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Narra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E.","family":"Rosko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4924-8990","authenticated-orcid":false,"given":"Mark","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3152-1189","authenticated-orcid":false,"given":"Heather","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-8731","authenticated-orcid":false,"given":"Saad","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo C.","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othman S.","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"1496_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410\u201327.","journal-title":"Lancet"},{"key":"1496_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","volume":"78","author":"IS Nijhof","year":"2018","unstructured":"Nijhof IS, van de Donk N, Zweegman S, Lokhorst HM. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018;78:19\u201337.","journal-title":"Drugs"},{"key":"1496_CR3","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3324\/haematol.2015.129189","volume":"101","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101:396\u2013406.","journal-title":"Haematologica"},{"key":"1496_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"1496_CR5","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41:1265\u201374.","journal-title":"J Clin Oncol"},{"key":"1496_CR6","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","volume":"41","author":"Y Lin","year":"2023","unstructured":"Lin Y, Martin TG, Usmani SZ, Berdeja JG, Jakubowiak AJ, Agha ME, et al. CARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma [Meeting Abstract 2023 ASCO Annual Meeting I]. J Clin Oncol. 2023;41:8009 https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8009. 2023\/06\/01.","journal-title":"J Clin Oncol"},{"key":"1496_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335\u201347.","journal-title":"N Engl J Med"},{"key":"1496_CR8","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","volume":"43","author":"S Jagannath","year":"2025","unstructured":"Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, et al. Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2025;43:2766\u201371.","journal-title":"J Clin Oncol"},{"key":"1496_CR9","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/bjh.19302","volume":"204","author":"D Dima","year":"2024","unstructured":"Dima D, Rashid A, Davis JA, Shune L, Abdallah AO, Li H, et al. Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study. Br J Haematol. 2024;204:1293\u20139.","journal-title":"Br J Haematol"},{"key":"1496_CR10","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, et al. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium. J Clin Oncol. 2023;41:2087\u201397.","journal-title":"J Clin Oncol"},{"key":"1496_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2025;145:85\u201397.","journal-title":"Blood"},{"key":"1496_CR12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1182\/blood.2024026216","volume":"146","author":"S Sidana","year":"2025","unstructured":"Sidana S, Ahmed N, Akhtar OS, Brazauskas R, Oloyede T, Bye M, et al. Standard-of-care idecabtagene vicleucel for relapsed\/refractory multiple myeloma. Blood. 2025;146:167\u201377.","journal-title":"Blood"},{"key":"1496_CR13","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1200\/JCO-24-01730","volume":"43","author":"DK Hansen","year":"2025","unstructured":"Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, et al. Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma. J Clin Oncol. 2025;43:1597\u2013609.","journal-title":"J Clin Oncol"},{"key":"1496_CR14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3324\/haematol.2023.283940","volume":"109","author":"S Sidana","year":"2024","unstructured":"Sidana S, Peres LC, Hashmi H, Hosoya H, Ferreri C, Khouri J, et al. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment. Haematologica. 2024;109:777\u201386.","journal-title":"Haematologica"},{"key":"1496_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","volume":"17","author":"S Zanwar","year":"2024","unstructured":"Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, et al. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. J Hematol Oncol. 2024;17:42.","journal-title":"J Hematol Oncol"},{"key":"1496_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1496_CR17","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e46.","journal-title":"Lancet Oncol"},{"key":"1496_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"AD Cohen","year":"2023","unstructured":"Cohen AD, Mateos MV, Cohen YC, Rodriguez-Otero P, Paiva B, van de Donk N, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023;141:219\u201330.","journal-title":"Blood"},{"key":"1496_CR19","doi-asserted-by":"publisher","first-page":"308.e1","DOI":"10.1016\/j.jtct.2023.12.016","volume":"30","author":"D Dima","year":"2024","unstructured":"Dima D, Davis JA, Ahmed N, Jia X, Sannareddy A, Shaikh H, et al. Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: A real-world experience. Transplant Cell Ther. 2024;30:308.e1\u2013.e13.","journal-title":"Transplant Cell Ther"},{"key":"1496_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01314-9","volume":"15","author":"D Dima","year":"2025","unstructured":"Dima D, Vazquez-Martinez MA, Davis JA, Goel U, Afrough A, Sannareddy A, et al. Outcomes of teclistamab in patients with relapsed\/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood Cancer J. 2025;15:111.","journal-title":"Blood Cancer J"},{"key":"1496_CR21","doi-asserted-by":"crossref","unstructured":"Razzo, BM, Midha, S, Portuguese, AJ, Grajales-Cruz, AF, De Menezes Silva Corraes, A, Costello, P, et al. Real-world experience with teclistamab for relapsed\/refractory multiple myeloma from the U.S. Myeloma Immunotherapy Consortium. Blood Cancer Discov. 2025;6:561\u201371.","DOI":"10.1158\/2643-3230.BCD-24-0354"},{"key":"1496_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023;13:117.","journal-title":"Blood Cancer J"},{"key":"1496_CR23","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/bjh.19505","volume":"205","author":"B Ferment","year":"2024","unstructured":"Ferment B, Lambert J, Caillot D, Lafon I, Karlin L, Lazareth A, et al. French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed\/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry. Br J Haematol. 2024;205:990\u20138.","journal-title":"Br J Haematol"},{"key":"1496_CR24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","volume":"39","author":"LJ Costa","year":"2025","unstructured":"Costa LJ, Banerjee R, Mian H, Weisel K, Bal S, Derman BA, et al. International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025;39:543\u201354.","journal-title":"Leukemia"},{"key":"1496_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1182\/blood-2024-201288","volume":"144","author":"F Maura","year":"2024","unstructured":"Maura F, Freeman CL, Lee H, Maclachlan KH, Durante M, Ziccheddu B, et al. Genomic determinants of resistance to anti-BCMA chimeric antigen receptor T-cell (CART) therapies in patients with relapsed\/refractory multiple myeloma. Blood. 2024;144:247.","journal-title":"Blood"},{"key":"1496_CR26","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29:2295\u2013306.","journal-title":"Nat Med"},{"key":"1496_CR27","first-page":"1514","volume":"109","author":"H Hashmi","year":"2024","unstructured":"Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, et al. Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed\/refractory multiple myeloma: US myeloma immunotherapy consortium real world experience. Haematologica. 2024;109:1514\u201324.","journal-title":"Haematologica"},{"key":"1496_CR28","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1200\/JCO.23.02232","volume":"42","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, et al. Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:1665\u201375.","journal-title":"J Clin Oncol"},{"key":"1496_CR29","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1182\/blood.2024024965","volume":"145","author":"CL Freeman","year":"2025","unstructured":"Freeman CL, Noble J, Menges M, Villanueva R, Nakashima JY, Figura NB, et al. Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes. Blood. 2025;145:1645\u201357.","journal-title":"Blood"},{"key":"1496_CR30","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002\u201314.","journal-title":"N Engl J Med"},{"key":"1496_CR31","doi-asserted-by":"crossref","unstructured":"Portuguese AJ Liang EC Huang JJ Jeon Y Dima D Banerjee R et al. Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma. Haematologica. 2025;110:3065\u2013077.","DOI":"10.3324\/haematol.2025.287985"},{"key":"1496_CR32","doi-asserted-by":"crossref","unstructured":"Ailawadhi S Anderson LD Dhakal B Shune L Sborov DW Hansen DK. Optimizing selection of bridging therapies prior to CAR-T therapy administration for multiple myeloma: clinical pearls from an expert roundtable. Clin Lymphoma Myeloma Leuk. 2025;26:85\u201393.","DOI":"10.1016\/j.clml.2025.08.005"},{"key":"1496_CR33","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/S2152-2650(23)01626-9","volume":"23","author":"H Einsele","year":"2023","unstructured":"Einsele H, Rodriguez-Otero P, Arnulf B, Patel K, Manier S, Costa L, et al. P-008 Idecabtagene vicleucel (ide-cel) vs standard regimens in triple-class\u2013exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis in patients receiving bridging therapy. Clin Lymphoma Myeloma Leuk. 2023;23:S37.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1496_CR34","doi-asserted-by":"publisher","first-page":"S566","DOI":"10.1016\/S2152-2650(24)01698-7","volume":"24","author":"Y Lin","year":"2024","unstructured":"Lin Y, Leleu X, Gatt M, Karlin L, Spencer A, Iida S, et al. MM-522 effectiveness of bridging therapy corresponds to improved outcomes after receiving CAR-T therapy: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2024;24:S566\u2013S7.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1496_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00993-0","volume":"14","author":"A Afrough","year":"2024","unstructured":"Afrough A, Hashmi H, Hansen DK, Sidana S, Ahn C, Peres LC, et al. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J. 2024;14:63.","journal-title":"Blood Cancer J"},{"key":"1496_CR36","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1182\/blood-2023-187565","volume":"142","author":"S Midha","year":"2023","unstructured":"Midha S, Gurumurthi A, Costello P, Redd RA, Freeman CLL, Castaneda O, et al. Alternative lymphodepletion strategies lead to similar response rates and toxicities in standard-of-care BCMA-directed CAR-T therapy in relapsed refractory multiple myeloma [Abstract from the 65th ASH Annual Meeting]. Blood. 2023;142:3499. https:\/\/doi.org\/10.1182\/blood-2023-187565.","journal-title":"Blood"},{"key":"1496_CR37","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory hodgkin lymphoma. J Clin Oncol. 2020;38:3794\u2013804.","journal-title":"J Clin Oncol"},{"key":"1496_CR38","unstructured":"Janssen Pharma: CARVYKTI (ciltacabtagene autoleucel). Package insert. Accessed 13 June 2023. https:\/\/www.fda.gov\/media\/156560\/download."},{"key":"1496_CR39","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1182\/blood-2023-178743","volume":"142","author":"NW Van De Donk","year":"2023","unstructured":"Van De Donk NW, Sidana S, Schecter JM, Jackson CC, Lendvai N, De Braganca KC, et al. Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and cartitude-4 studies of ciltacabtagene autoleucel (cilta-cel) [Abstract 65th ASH Annual Meeting]. Blood. 2023;142:3501. https:\/\/doi.org\/10.1182\/blood-2023-178743.","journal-title":"Blood"},{"key":"1496_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD, G\u00e1llego P\u00e9rez-Larraya J, van de Donk N, Arnulf B, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12:32.","journal-title":"Blood Cancer J"},{"key":"1496_CR41","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1182\/bloodadvances.2024015721","volume":"9","author":"K Kelly","year":"2025","unstructured":"Kelly K, Cooperrider JH, Bishop MR, Kosuri S, Jakubowiak A, Derman BA. Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood Adv. 2025;9:3613\u20136.","journal-title":"Blood Adv"},{"key":"1496_CR42","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood.2023021429","volume":"142","author":"CE Graham","year":"2023","unstructured":"Graham CE, Lee WH, Wiggin HR, Supper VM, Leick MB, Birocchi F, et al. Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood. 2023;142:1248\u201352.","journal-title":"Blood"},{"key":"1496_CR43","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1182\/blood.2023021860","volume":"142","author":"J Gust","year":"2023","unstructured":"Gust J. BCMA-CAR T-cell treatment\u2013associated parkinsonism. Blood. 2023;142:1181\u20133.","journal-title":"Blood"},{"key":"1496_CR44","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/S2152-2650(25)03409-3","volume":"25","author":"H Hosoya","year":"2025","unstructured":"Hosoya H, Velayati A, Dima D, Jensen A, Portuguese A, Hovanky V, et al. Rapid peak CAR-T expansion is associated with delayed neurotoxicity following ciltacabtagene autoleucel in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2025;25:S4.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1496_CR45","doi-asserted-by":"publisher","first-page":"5953","DOI":"10.1182\/blood-2025-5953","volume":"146","author":"KJ Lim","year":"2025","unstructured":"Lim KJ, Parrondo R, Chhabra S, Dooley K, De Menezes Silva Corraes A, Carabenciov D, et al. Prophylactic dexamethasone to reduce risk of cilta-cel associated immune effector cell delayed neurotoxicity. Blood. 2025;146:5953.","journal-title":"Blood"},{"key":"1496_CR46","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.1182\/blood-2025-5856","volume":"146","author":"K Feliciano Salva","year":"2025","unstructured":"Feliciano Salva K, Copponex C, Whiting J, Hansen D, Freeman CL, Castaneda Puglianini OA, et al. Suppressive dexamethasone (SupDex) to prevent delayed non-icans delayed neurotoxicity (DNT) post ciltacabtagene-autoleucel(cilta-cel) in patients with relapsed myeloma.suppressive dexamethasone (SupDex) to prevent delayed non-icans delayed neurotoxicity (DNT) post ciltacabtagene-autoleucel(cilta-cel) in patients with relapsed myeloma. Blood. 2025;146:5856.","journal-title":"Blood"},{"key":"1496_CR47","unstructured":"U.S. Food & Drug Administration (FDA). FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Immunotherapies [Internet]. Washington DC; 2023. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous."},{"key":"1496_CR48","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1182\/blood-2023-178806","volume":"142","author":"SJ Harrison","year":"2023","unstructured":"Harrison SJ, Nguyen T, Rahman M, Er J, Li J, Li K, et al. CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma [Abstract from the 65th ASH Annual Meeting]. Blood. 2023;142:6939. https:\/\/doi.org\/10.1182\/blood-2023-178806.","journal-title":"Blood"},{"key":"1496_CR49","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1182\/blood.2024024166","volume":"143","author":"M Elsallab","year":"2024","unstructured":"Elsallab M, Ellithi M, Lunning MA, Perales MA, D\u2019Angelo C, Ma J, et al. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA adverse events reporting system. Blood. 2024;143:2099\u2013105.","journal-title":"Blood"},{"key":"1496_CR50","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette JJD, Caponetti GC, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med. 2024;30:984\u20139.","journal-title":"Nat Med"},{"key":"1496_CR51","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","volume":"390","author":"M Ozdemirli","year":"2024","unstructured":"Ozdemirli M, Loughney TM, Deniz E, Chahine JJ, Albitar M, Pittaluga S, et al. Indolent CD4+ CAR T-cell lymphoma after cilta-cel CAR T-cell therapy. N Engl J Med. 2024;390:2074\u201382.","journal-title":"N Engl J Med"},{"key":"1496_CR52","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJMoa2411507","volume":"392","author":"K Perica","year":"2025","unstructured":"Perica K, Jain N, Scordo M, Patel R, Eren OC, Patel U, et al. CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53. N Engl J Med. 2025;392:577\u201383.","journal-title":"N Engl J Med"},{"key":"1496_CR53","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas Dos Santos","year":"2024","unstructured":"Cordas Dos Santos DM, Tix T, Shouval R, Gafter-Gvili A, Alberge JB, Cliff ERS, et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024;30:2667\u201378.","journal-title":"Nat Med"},{"key":"1496_CR54","first-page":"184","volume":"111","author":"D Dima","year":"2026","unstructured":"Dima D, Logue JM, Waqar SHB, Peres LC, Colin-Leitzinger CM, De Avila G, et al. Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma. Haematologica. 2026;111:184\u201395.","journal-title":"Haematologica"}],"updated-by":[{"DOI":"10.1038\/s41408-026-01605-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000}}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01496-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01496-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01496-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:32:21Z","timestamp":1788240741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01496-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1496"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01496-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In this article the author name \u2018Larry D. Anderson, Jr\u2019 has been published as \u2018Larry Anderson\u2019.","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":10,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":11,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41408-026-01605-9","URL":"https:\/\/doi.org\/10.1038\/s41408-026-01605-9","order":13,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DKH receives research funding from Bristol Myers Squibb, Janssen, Kite Pharma, Karyopharm, and Adaptive Biotech, and reports consulting or advisory roles with Bristol Myers Squibb, Janssen, Legend Biotech, Pfizer, Kite Pharma\/Gilead Sciences, AstraZeneca, and Karyopharm. DD reports consulting for Karyopharm and Caribou Biosciences. HM receives honoraria from Bristol Myers Squibb, Pfizer, Janssen, Amgen, Takeda, GSK, FORUS, and Sanofi, and research funding from Pfizer and Janssen. AA receives research funding from AbbVie, Regeneron Pharmaceuticals, K36-Therapeutics, Janssen, and Adaptive Biotech, and honoraria from Karyopharm, Bristol Myers Squibb, Janssen, Sanofi, and Pfizer. NA receives research funding from Kite\/Gilead and Pfizer and has consulting or advisory roles with Bristol Myers Squibb, Kite\/Gilead, Invivyd Bio, Legend Bio, Johnson & Johnson, Autolus, and ADC Therapeutics; founder of Cortex (non-profit) and board member of USMIRC. LA receives consulting fees and honoraria from Pfizer, Bristol Myers Squibb, BeiGene, Sanofi, Amgen, Karyopharm, Celgene, Prothena, Cellectar, Johnson & Johnson, GSK, and AbbVie, and research funding from Bristol Myers Squibb, BeiGene, Johnson & Johnson, GSK, and AbbVie. RB reports consulting for AbbVie, Adaptive Biotech, Bristol Myers Squibb, Caribou Biosciences, Genentech, Gilead\/Kite, GSK, Janssen, Karyopharm, Legend Biotech, Pfizer, Poseida Therapeutics, Sanofi, and SparkCures, and receives research funding from AbbVie, Bristol Myers Squibb, Janssen, Novartis, Pack Health, Prothena, and Sanofi. MM is supported by the Advancing a Healthier Wisconsin CTSI KL2 award, receives institutional research funding from Sanofi, Bristol Myers Squibb, and Celgene, and reports consulting for Sanofi, Bristol Myers Squibb\/Celgene, Pfizer, Janssen Scientific Affairs, Legend Biotech, and Adaptive Biotech. SS reports consulting for Janssen, Bristol Myers Squibb, Legend, Magenta Therapeutics, Sanofi, Pfizer, Takeda, Kite, AbbVie, Regeneron, BiolineRx, and Genentech\/Roche, and receives research funding from Janssen, Magenta Therapeutics, Allogene Therapeutics, Novartis, and Bristol Myers Squibb. KKP reports consulting for Bristol Myers Squibb, Janssen, Pfizer, Arcellx, and Karyopharm Therapeutics, research funding from Bristol Myers Squibb, Poseida Therapeutics, Takeda, Janssen, Cellectis, Nektar, AbbVie\/Genentech, Precision Biosciences, and Allogene Therapeutics, and travel support from Bristol Myers Squibb. ASM reports consulting for Bristol Myers Squibb. MCP receives honoraria from Gilead and research funding from Kite\/Gilead, Janssen, Bristol Myers Squibb, and Novartis. HH reports consulting for Bristol Myers Squibb, Sanofi, and Janssen. YE receives honoraria from Pfizer, GSK, Kite, Janssen, Sanofi, Bristol Myers Squibb, Orca, and Oncopeptides, and research funding via Pharmacyclics (Alliance) and GSK (Alliance). BD receives honoraria from Natera, GlaxoSmithKline, Menarini, Kite, and Janssen, consulting for Genentech, Caribou, Johnson & Johnson, Karyopharm, Bristol Myers Squibb, Janssen, Arcellx, and Pfizer, and research funding from Caribou, Ichnos, Kite, Carsgen, Bristol Myers Squibb, Janssen, Arcellx, and Pfizer. SU reports consulting or advisory roles with GSK, Takeda, SecuraBio, Amgen, Seagen, Johnson & Johnson\/Janssen, Genentech, Sanofi, Gilead, Oncopeptides, Bristol Myers Squibb\/Celgene, SkylineDX, AbbVie, EdoPharma, Gracell Therapeutics, TeneoBio, and AstraZeneca, and receives research funding from Janssen, Takeda, SecuraBio, Amgen, Seagen, Johnson & Johnson\/Janssen, Sanofi, Gilead, Oncopeptides, Bristol Myers Squibb\/Celgene, SkylineDX, AbbVie, EdoPharma, Gracell Therapeutics, and TeneoBio. OSA reports advisory board participation for Sanofi and Janssen, and consulting for Immix Biopharma. All remaining authors report no financial relationships relevant to this work.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All Center for International Blood and Marrow Transplant Research studies are reviewed and approved by the National Marrow Donor Program Institutional Review Board, and all patients (or their legal guardians) provided informed consent for data collection and research.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"80"}}